Association Between Papillary Thyroid Cancer and Primary Aldosteronism in Individuals With Hypertension

Autor(es):Mostrar menos -

Maciel, Ana Alice W. ; Danilovic, Debora L. S. ; Soares, Ibere C. ; Freitas, Thais C. ; Okubo, Jessica ; Fagundes, Gustavo F. C. ; Freitas-Castro, Felipe ; Santana, Lucas S. ; Guimaraes, Augusto G. ; Calsavara, Vinicius F. ; Ledesma, Felipe L. ; Castroneves, Luciana A. ; Coelho, Fernando M. A. ; Srougi, Victor ; Tanno, Fabio Y. ; Chambo, Jose L. ; Carnevale, Francisco C. ; Silveira, Joao, V ; Consolim-Colombo, Fernanda M. ; Bortolotto, Luiz A. ; Brito, Luciana P. ; Fragoso, Maria Candida B., V ; Drager, Luciano F. ; Gomez-Sanchez, Celso E. ; Latronico, Ana Claudia ; Mendonca, Berenice B. ; Hoff, Ana O. ; Almeida, Madson Q.

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM; v. N/A, p. 12-pg., 2024-09-30.

Resumo

Context: Aldosterone excess chronically induces oxidative stress and cell proliferation. Previously, a single study investigated primary aldosteronism (PA) in patients with papillary thyroid cancer (PTC), albeit without a matched control group. Objective: We conducted a propensity score-matched, case-control study to investigate the association between PA and PTC in individuals with arterial hypertension (HT). Methods: PA was investigated in 137 patients with PTC and HT. The control group included 137 (1:1) age-, sex-, and body mass index-matched individuals with HT. We conducted a secondary analysis in which controls were also matched according to HT stage. Results: The prevalence of PA was 29.20% (95% CI, 21.91%-37.68%) in the PTC group and 20.44% (95% CI, 14.22%-28.35%) in the controls not matched by HT stage (P = .093). Although the PA prevalence was similar in both groups, the frequency of severe HT (stage III or resistant) was significantly lower in the PTC group (23%) compared to the HT controls (73%; P < .001). After matching the controls by HT stage, the prevalence of PA in the PTC group was significantly higher compared to the hypertensive controls (9.56%; 95% CI, 5.39%-16.1%; P < .0001). In the multivariable analysis, PTC was independently associated with PA both in unmatched HT individuals (odds ratio [OR] 4.74; 95% CI, 2.26-10.55; P < .001) and in those matched by HT stage (OR 5.88; 95% CI, 2.79-13.37; P < .001). Conclusion: PTC was an independent variable associated with a diagnosis of PA in HT individuals. Therefore, we propose the association between PTC and HT as a new recommendation for PA screening regardless of HT severity. (AU)

• Processo FAPESP: 21/10101-5 - Investigação de novas alterações genética associadas à patogênese dos Aldosteronomas por sequenciamento exômico
• Beneficiário: Augusto Garcia Guimarães
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 21/11240-9 - Sequenciamento completo do exoma para investigação de novas causas genéticas dos Feocromocitomas e Paragangliomas metastáticos
• Beneficiário: Felipe Freitas de Castro
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 21/10363-0 - Sequenciamento completo do exoma para investigação de novas causas genéticas do Hiperaldosteronismo primário causado por hiperplasia adrenal bilateral
• Beneficiário: Lucas Santos de Santana
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 19/15873-6 - Investigação de novos aspectos genéticos, clínicos e anatomopatológicos da hipertensão arterial de origem endócrina
• Beneficiário: Madson Queiroz Almeida
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 21/09879-1 - Investigação clínica e genética da associação entre Hiperaldosteronismo Primário e Câncer Papilífero de Tireoide
• Beneficiário: Ana Alice Wolf Maciel
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto